GeneDx Holdings - Class A opened lower at $55.03, compared with its previous close of $55.12. In the last trading session, the stock traded between $51.26 and $55.03. It showed a downward intraday trend.
An investment of $100 made 4 years ago in GeneDx Holdings - Class A is now worth
$ 455.64
Giving a profit of
$ 355.64 (355.64%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-3.10 (-5.62%)
Day High
$55.03
Day Low
$51.26
Day Open
$55.03
Prev Close
$55.12
Volume
7,98,485
1W Return
-25.08%
1M Return
-18.53%
3M Return
-36.39%
6M Return
31.34%
1Y Return
-62.82%
Market Cap ($ Mn)
1,559
PE Ratio
-
PB Ratio
10.53
PEG Ratio
-
ROE
-7.62%
ROCE
-4.76%
EPS (TTM)
$-0.41
1 Week
-25.08%
1 Month
-18.53%
3 Months
-36.39%
6 Months
31.34%
9 Months
-43.10%
BTIG lowers GeneDx price target to $85, maintains Buy rating
BTIG analyst Mark Massaro maintained a Buy rating on GeneDx Holdings. The price target was lowered from $90 to $85. The revised target reflects a $5 reduction in valuation expectations.
2 days agoGeneDx affirms FY26 sales guidance of $475M-$490M vs $482M est
GeneDx Holdings affirmed FY2026 sales guidance of $475 million to $490 million. Reaffirmed outlook sits below the analyst consensus estimate of $482.324 million. Q3FY26 adjusted net income reached $8.6 million, improving from prior quarters. Adjusted gross margin expanded to 72%, driven by a 5% rise in average reimbursement rate.
3 days agoGeneDx plans long-read genome testing launch by year-end
GeneDx plans to launch long-read whole genome sequencing by year-end. Technology targets structural variants missed by short-read sequencing. Early access program uses phenotype-driven approach to reduce sequential testing. Integration aims to accelerate diagnosis using GeneDx Infinity™ insights.
23 days agoGeneDx to present 27 abstracts at ASHG 2026 annual meeting
GeneDx Holdings Corp will present 27 scientific abstracts at the ASHG 2026 Annual Meeting. Research focuses on scaling genomic interpretation with AI and establishing sequencing as standard of care. Key studies include analysis of over 100,000 autism cases and newborn screening data from 19,000 infants. The company secured three platform presentations and a top-tier Reviewer’s Choice poster.
24 days agoGeneDx presents new evidence advancing genomic newborn screening
GeneDx presented new GUARDIAN study data at ICoNS 2026 involving 30,000 newborns. Parent participation rate reached 72.3%, with 76% of participants of non-European ancestry. Genomic screening identified treatable conditions like Long QT syndrome missed by standard tests. BRIDGES-NBS program launches enrollment for 777 genetic conditions across eight states.
1mo agoGeneDx CEO Katherine Stueland named 2026 Fierce 50 honoree
Katherine Stueland, CEO of GeneDx, named a 2026 Fierce 50 honoree for Health Equity. Recognition highlights leadership in integrating genomics into standard healthcare. GeneDx leverages GeneDx Infinity, the world’s largest rare disease genomic dataset. Company’s ExomeDx and GenomeDx tests hold FDA Breakthrough Device designation. Fierce 50 awards are now in their fourth year of recognizing industry impact.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $717.71 | -0.07% | $2,65,923.04M | 33.49 | |
| $235.31 | -0.34% | $1,65,547.88M | 38.52 | |
| $702.59 | +0.85% | $55,354.26M | 39.00 | |
| $176.95 | -0.52% | $49,887.34M | 30.34 | |
| $319.82 | +2.51% | $46,375.50M | - | |
| $470.90 | -0.97% | $46,282.88M | 104.98 | |
| $274.53 | -0.23% | $45,242.54M | 32.52 | |
| $1,749.01 | -0.14% | $34,787.81M | 31.52 | |
| $212.93 | -0.92% | $32,195.02M | 40.22 | |
| $372.23 | +0.36% | $30,225.08M | 27.72 | |
| $258.69 | +0.10% | $28,460.82M | 25.77 | |
| $154.78 | -0.37% | $20,939.57M | - |
An investment of $100 made 4 years ago in GeneDx Holdings - Class A is now worth
$ 455.64
Giving a profit of
$ 355.64 (355.64%)
Note: Past profits do not guarantee future returns.
